Summary
Pegging drug prices here to those in other countries would yield minimal savings for the United States and devastate funding for biomedical research.
Source: Forbes
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
